Home>>Signaling Pathways>> Others>>SGN-2FF

SGN-2FF

Catalog No.GC33031

SGN-2FF is a potent and orally active inhibitor of fucosylation, directly inhibits fucosyltransferase activity. SGN-2FF possesses antitumor activity.

Products are for research use only. Not for human use. We do not sell to patients.

SGN-2FF Chemical Structure

Cas No.: 2089647-47-0

Size Price Stock Qty
5mg
$162.00
In stock
10mM (in 1mL Water)
$178.00
In stock
25mg
$518.00
In stock
50mg
$828.00
In stock
100mg
$1,328.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

SGN-2FF is an oral inhibitor of fucosylation, directly inhibits fucosyltransferase activity, and possesses antitumor activity.

SGN-2FF (2-Fluorofucose) is an inhibitor of fucosylation, inhibits cellular fucosylation by depleting the fucosylation substrate GDP-fucose, and by direct inhibition of fucosyltransferases, and leads to the production of afucosylated glycoproteins including antibodies. SGN-2FF activates human T cells in an antigen-dependent manner[1].

SGN-2FF exhibits antitumor activity in multiple mouse tumor models, showing substantial tumor growth delay. SGN-2FF elevates the protective effect of a lymphoma vaccine in a syngeneic mouse model[1].

[1]. Stephen C. Alley, et al. Abstract DDT02-02: SGN-2FF: A novel small molecule inhibitor of fucosylation with preclinical antitumor activity through multiple immune mechanisms. Cancer Res 2017;77(13 Suppl).

Reviews

Review for SGN-2FF

Average Rating: 5 ★★★★★ (Based on Reviews and 8 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for SGN-2FF

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.